Transactions
2
Insider / ABBOTT LABORATORIES
Conroy Kevin T
Director at ABBOTT LABORATORIES · ABT
Conroy Kevin T, Director at ABBOTT LABORATORIES, has disclosed 2 transactions in ABT since July 1, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $5.5M at the reported prices. The latest was filed September 25, 2026, 2 days after the trade.
Open-market buys
0
Sales
1
Avg. disclosure lag
1.5d
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| ABT | Sell F | September 23, 2026 | September 25, 2026 | 2d | 52,507 | $104 | $5.5M | Form 4 ↗ | |
| ABT | Other A | June 30, 2026 | July 1, 2026 | 1d | 231 | $91 | $21K | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 25, 2026 | Form 4 | 0001306119-26-000009 | 1 | published | EDGAR ↗ |
| July 1, 2026 | Form 4 | 0001306119-26-000006 | 1 | published | EDGAR ↗ |
Sources and method
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.